{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T17:27:50Z","timestamp":1791912470680,"version":"4.3.4"},"reference-count":28,"publisher":"BMJ","issue":"2","license":[{"start":{"date-parts":[[2025,11,26]],"date-time":"2025-11-26T00:00:00Z","timestamp":1764115200000},"content-version":"unspecified","delay-in-days":148,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Neurol Open"],"accepted":{"date-parts":[[2025,11,6]]},"published-print":{"date-parts":[[2025,7]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Myasthenia gravis (MG) is a rare autoimmune disorder that affects neuromuscular transmission, leading to muscle weakness. While most patients respond to standard treatments, approximately 15% remain refractory, prompting interest in alternative therapies. This study examined the use of rituximab in patients with refractory MG at a single centre in Latvia, intending to broaden discussions on treatment strategies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and methods<\/jats:title>\n                    <jats:p>The prospective cohort study was conducted at Pauls Stradi\u0146\u0161 Clinical University Hospital from November 2022 to March 2024. Refractory MG was defined as failure to achieve adequate disease control despite standard immunosuppressive therapy, including patients with persistent symptoms, recurrent crises or intolerance to medications. Myasthenia Gravis Composite Score (MGCS), Myasthenia Gravis Activities of Daily Living and Myasthenia Gravis Quality of Life (scores at baseline and monthly for 6 months) were completed. Glucocorticosteroid doses were also recorded. Data were analysed using descriptive statistics and Wilcoxon signed-rank test, considering p&lt;0.05 significant.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>98 patients with MG were evaluated to identify treatment-refractory cases. A total of nine patients with refractory MG (median disease duration 7 years, range 1\u201312) were included and received a single low dose of rituximab. Among the nine patients treated, seven were acetylcholine receptor-positive and two were muscle-specific kinase antibody-seropositive. 6 months after treatment, the median MGCS decreased from 11.5 (IQR 7.3\u201317.8) to 7.5 (IQR 3.8\u20138.0) (p=0.025). The median daily corticosteroid dose decreased from 15.0\u2009mg (IQR 10.0\u201320.9) to 8.5\u2009mg (IQR 5.0\u201312.5) (p=0.036). There were no exacerbations of MG or significant adverse reactions.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Our findings suggest that rituximab may be a promising treatment option for refractory MG. The notable clinical benefits and safety profile make rituximab a valuable addition to this challenging autoimmune disorder treatment options. Further research is needed to refine patient selection and dosing for optimal treatment outcomes.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjno-2025-001130","type":"journal-article","created":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T06:10:16Z","timestamp":1764569416000},"page":"e001130","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":1,"title":["Exploring rituximab for the treatment of refractory myasthenia gravis: a single-centre experience"],"prefix":"10.1136","volume":"7","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9416-1600","authenticated-orcid":false,"given":"Marija","family":"Roddate","sequence":"first","affiliation":[{"name":"Neurology, Paul Stradins Clinical University Hospital, Riga, Latvia"},{"name":"Riga Stradins University, Riga, Latvia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Violeta","family":"\u017dukova","sequence":"additional","affiliation":[{"name":"Neurology, Paul Stradins Clinical University Hospital, Riga, Latvia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arta","family":"Grosmane","sequence":"additional","affiliation":[{"name":"Neurology, Paul Stradins Clinical University Hospital, Riga, Latvia"},{"name":"Riga Stradins University, Riga, Latvia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gundega","family":"\u0136au\u0137e","sequence":"additional","affiliation":[{"name":"Neurology, Paul Stradins Clinical University Hospital, Riga, Latvia"},{"name":"Riga Stradins University, Riga, Latvia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ieva","family":"Gl\u0101zere","sequence":"additional","affiliation":[{"name":"Neurology, Paul Stradins Clinical University Hospital, Riga, Latvia"},{"name":"Riga Stradins University, Riga, Latvia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna Rostedt","family":"Punga","sequence":"additional","affiliation":[{"name":"Department of Medical Sciences, Clinical Neurophysiology, Uppsala University, Uppsala, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Viktorija","family":"\u0136\u0113ni\u0146a","sequence":"additional","affiliation":[{"name":"Neurology, Paul Stradins Clinical University Hospital, Riga, Latvia"},{"name":"Riga Stradins University, Riga, Latvia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2025,11,30]]},"reference":[{"key":"2025113022101210000_7.2.e001130.1","doi-asserted-by":"crossref","DOI":"10.1186\/1471-2377-10-46","article-title":"A systematic review of population based epidemiological studies in Myasthenia Gravis","volume":"10","author":"Carr","year":"2010","journal-title":"BMC Neurol"},{"key":"2025113022101210000_7.2.e001130.2","doi-asserted-by":"publisher","DOI":"10.1159\/000279334"},{"key":"2025113022101210000_7.2.e001130.3","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1111\/ene.13535","article-title":"A nationwide epidemiological study of myasthenia gravis in Latvia","volume":"25","author":"Zieda","year":"2018","journal-title":"Eur J Neurol"},{"key":"2025113022101210000_7.2.e001130.4","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(15)00145-3"},{"key":"2025113022101210000_7.2.e001130.5","doi-asserted-by":"publisher","DOI":"10.1097\/CND.0000000000000257"},{"key":"2025113022101210000_7.2.e001130.6","doi-asserted-by":"publisher","DOI":"10.1038\/nrd3003"},{"key":"2025113022101210000_7.2.e001130.7","doi-asserted-by":"publisher","DOI":"10.1111\/ajt.12220"},{"key":"2025113022101210000_7.2.e001130.8","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2021.736190","article-title":"Effectiveness and Safety of Rituximab for Refractory Myasthenia Gravis: A Systematic Review and Single-Arm Meta-Analysis","volume":"12","author":"Zhao","year":"2021","journal-title":"Front Neurol"},{"key":"2025113022101210000_7.2.e001130.9","doi-asserted-by":"crossref","unstructured":"Feng X , Song Z , Wu M , et al . Efficacy and Safety of Immunotherapies in Refractory Myasthenia Gravis: A Systematic Review and Meta-Analysis. Front Neurol 2021;12. doi:10.3389\/fneur.2021.725700","DOI":"10.3389\/fneur.2021.725700"},{"key":"2025113022101210000_7.2.e001130.10","doi-asserted-by":"publisher","DOI":"10.1002\/mus.25597"},{"key":"2025113022101210000_7.2.e001130.11","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.jneuroim.2008.04.039","article-title":"Sustained response to Rituximab in anti-AChR and anti-MuSK positive Myasthenia Gravis patients","volume":"201\u2013202","author":"Illa","year":"2008","journal-title":"J Neuroimmunol"},{"key":"2025113022101210000_7.2.e001130.12","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1001\/jamaneurol.2022.2887","article-title":"Efficacy and Safety of Rituximab for New-Onset Generalized Myasthenia Gravis","volume":"79","author":"Piehl","year":"2022","journal-title":"JAMA Neurol"},{"key":"2025113022101210000_7.2.e001130.13","doi-asserted-by":"crossref","DOI":"10.1111\/ene.16229","article-title":"Generalized myasthenia gravis with acetylcholine receptor antibodies: A guidance for treatment","volume":"31","author":"Gilhus","year":"2024","journal-title":"Eur J Neurol"},{"key":"2025113022101210000_7.2.e001130.14","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1212\/WNL.0b013e3181dc1b1e","article-title":"The MG Composite","volume":"74","author":"Burns","year":"2010","journal-title":"Neurology (ECronicon)"},{"key":"2025113022101210000_7.2.e001130.15","doi-asserted-by":"crossref","first-page":"2189","DOI":"10.3390\/jcm11082189","article-title":"Quality of Life in Myasthenia Gravis and Correlation of MG-QOL15 with Other Functional Scales","volume":"11","author":"Diez Porras","year":"2022","journal-title":"JCM"},{"key":"2025113022101210000_7.2.e001130.16","doi-asserted-by":"publisher","DOI":"10.1111\/j.1749-6632.2012.06817.x"},{"key":"2025113022101210000_7.2.e001130.17","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1097\/CND.0b013e3181df2b3e","article-title":"Rituximab in the treatment of MuSK antibody-positive myasthenia gravis","volume":"12","author":"Stein","year":"2011","journal-title":"J Clin Neuromuscul Dis"},{"key":"2025113022101210000_7.2.e001130.18","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.00613","article-title":"Long-Lasting Rituximab-Induced Reduction of Specific-But Not Total-IgG4 in MuSK-Positive Myasthenia Gravis","volume":"11","author":"Marino","year":"2020","journal-title":"Front Immunol"},{"key":"2025113022101210000_7.2.e001130.19","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.686466","article-title":"Short- and Long-Lived Autoantibody-Secreting Cells in Autoimmune Neurological Disorders","volume":"12","author":"Zografou","year":"2021","journal-title":"Front Immunol"},{"key":"2025113022101210000_7.2.e001130.20","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1212\/WNL.0b013e3182407982","article-title":"Long-lasting treatment effect of rituximab in MuSK myasthenia","volume":"78","author":"D\u00edaz-Manera","year":"2012","journal-title":"Neurology (ECronicon)"},{"key":"2025113022101210000_7.2.e001130.21","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1001\/jamaneurol.2016.4190","article-title":"Durability of the Rituximab Response in Acetylcholine Receptor Autoantibody-Positive Myasthenia Gravis","volume":"74","author":"Robeson","year":"2017","journal-title":"JAMA Neurol"},{"key":"2025113022101210000_7.2.e001130.22","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.jneuroim.2017.05.021","article-title":"Responsiveness to low-dose rituximab in refractory generalized myasthenia gravis","volume":"311","author":"Jing","year":"2017","journal-title":"J Neuroimmunol"},{"key":"2025113022101210000_7.2.e001130.23","doi-asserted-by":"crossref","first-page":"1596","DOI":"10.1007\/s00415-019-09296-y","article-title":"Rituximab as induction therapy in refractory myasthenia gravis: 18 month follow-up study","volume":"266","author":"Singh","year":"2019","journal-title":"J Neurol"},{"key":"2025113022101210000_7.2.e001130.24","doi-asserted-by":"publisher","DOI":"10.1177\/1756285611411503"},{"key":"2025113022101210000_7.2.e001130.25","doi-asserted-by":"crossref","DOI":"10.1186\/1477-7525-8-129","article-title":"Quality of life and life circumstances in German myasthenia gravis patients","volume":"8","author":"Twork","year":"2010","journal-title":"Health Qual Life Outcomes"},{"key":"2025113022101210000_7.2.e001130.26","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2020.553626","article-title":"Determinants of Quality of Life in Myasthenia Gravis Patients","volume":"11","author":"Szczudlik","year":"2020","journal-title":"Front Neurol"},{"key":"2025113022101210000_7.2.e001130.27","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2018-319410"},{"key":"2025113022101210000_7.2.e001130.28","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1212\/WNL.0000000000004341","article-title":"Rituximab as treatment for anti-MuSK myasthenia gravis","volume":"89","author":"Hehir","year":"2017","journal-title":"Neurology (ECronicon)"}],"container-title":["BMJ Neurology Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjno-2025-001130","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T06:10:23Z","timestamp":1764569423000},"score":1,"resource":{"primary":{"URL":"https:\/\/neurologyopen.bmj.com\/lookup\/doi\/10.1136\/bmjno-2025-001130"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":28,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2025,11,30]]},"published-print":{"date-parts":[[2025,7]]}},"alternative-id":["10.1136\/bmjno-2025-001130"],"URL":"https:\/\/doi.org\/10.1136\/bmjno-2025-001130","relation":{},"ISSN":["2632-6140"],"issn-type":[{"value":"2632-6140","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7]]}}}